Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AHPIOTCMKTS:ARTHOTCMKTS:RGINNASDAQ:VRAYQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAHPIAllied Healthcare Products$0.00$0.00▼$3.46$16K-2.3951,674 shsN/AARTHArch Therapeutics$0.00$0.13$0.16▼$1.57$6K4.024,068 shs2 shsRGINRegenicin$0.00$0.00▼$0.00N/AN/A35,003 shsN/AVRAYQViewRay$0.00$0.00▼$0.00$18K1.02616 shs13,041 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAHPIAllied Healthcare Products0.00%0.00%0.00%0.00%-98.66%ARTHArch Therapeutics0.00%0.00%+33.33%-99.49%-99.89%RGINRegenicin0.00%0.00%0.00%0.00%-98.00%VRAYQViewRay0.00%0.00%0.00%+3.00%+3.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAHPIAllied Healthcare ProductsN/AN/AN/AN/AN/AN/AN/AN/AARTHArch TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARGINRegenicinN/AN/AN/AN/AN/AN/AN/AN/AVRAYQViewRayN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAHPIAllied Healthcare Products 0.00N/AN/AN/AARTHArch Therapeutics 0.00N/AN/AN/ARGINRegenicin 0.00N/AN/AN/AVRAYQViewRay 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAHPIAllied Healthcare Products$27.05M0.00N/AN/A$1.30 per share0.00ARTHArch Therapeutics$80K0.07N/AN/A($2.43) per share0.00RGINRegenicinN/AN/AN/AN/AN/AN/AVRAYQViewRay$102.21M0.00N/AN/AN/ANaNCompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAHPIAllied Healthcare Products-$5.36M-$1.34N/AN/AN/AN/AN/AN/AN/AARTHArch Therapeutics-$6.98MN/A0.00∞N/A-8,257.70%N/A-730.22%8/18/2025 (Estimated)RGINRegenicin-$640KN/A0.00N/AN/AN/AN/AN/AN/AVRAYQViewRay-$107.33MN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAHPIAllied Healthcare ProductsN/AN/AN/AN/AN/AARTHArch TherapeuticsN/AN/AN/AN/AN/ARGINRegenicinN/AN/AN/AN/AN/AVRAYQViewRayN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAHPIAllied Healthcare ProductsN/AN/AN/AARTHArch TherapeuticsN/A0.100.01RGINRegenicinN/AN/AN/AVRAYQViewRayN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAHPIAllied Healthcare Products4.15%ARTHArch Therapeutics6.91%RGINRegenicin0.01%VRAYQViewRay15.47%Insider OwnershipCompanyInsider OwnershipAHPIAllied Healthcare Products5.10%ARTHArch Therapeutics4.50%RGINRegenicinN/AVRAYQViewRay2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAHPIAllied Healthcare Products1504.01 million3.81 millionNot OptionableARTHArch Therapeutics104.74 million4.53 millionNot OptionableRGINRegenicin3165.77 millionN/ANot OptionableVRAYQViewRay300183.40 million178.82 millionNo DataARTH, RGIN, VRAYQ, and AHPI HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWorkday Stock Price Implosion: An Automatic Buy for AI InvestorsBy Thomas Hughes | May 26, 2025View Workday Stock Price Implosion: An Automatic Buy for AI InvestorsGitLab: Buy It Low While You Still Can—Higher Prices Are ComingBy Thomas Hughes | June 11, 2025View GitLab: Buy It Low While You Still Can—Higher Prices Are ComingApple’s Quiet HomePad Delay Could Be Its Loudest Move YetBy Chris Markoch | June 1, 2025View Apple’s Quiet HomePad Delay Could Be Its Loudest Move YetQuantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?Qualcomm: A Technical Setup Is Emerging, and It's BullishBy Sam Quirke | June 18, 2025View Qualcomm: A Technical Setup Is Emerging, and It's BullishARTH, RGIN, VRAYQ, and AHPI Company DescriptionsAllied Healthcare Products NASDAQ:AHPIAllied Healthcare Products, Inc. engages in manufacturing respiratory products used in the health care industry in hospitals and alternate site settings, including sub-acute care facilities, home health care and emergency medical care. Its product line includes respiratory care products, medical gas equipment, and emergency medical products. The company was founded in 1979 and is headquartered in St. Louis, MO.Arch Therapeutics OTCMKTS:ARTH$0.0012 0.00 (0.00%) As of 06/18/2025Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.Regenicin OTCMKTS:RGINRegenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.ViewRay NASDAQ:VRAYQViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado. On July 16, 2023, ViewRay, Inc., alongwith its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. On October 26, 2023, the voluntary petition of ViewRay , Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on July 16, 2023. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
